| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_137632ce410f947dc83f29aa9ca2618f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-351
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3515 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-117
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-117
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00 |
| filingDate |
2021-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46a2fcd58ee53c792d2b62dbb7df1c6c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e465abb089e2d433b36785e31c07386
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af5337bcd37b7da6dd6c317922b94c85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2abd87b906706b3db063c0f2269acc26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf2b29875b0a5da24fcb528d20c7bba6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa33dee0663df9e15001837968fd6130
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e003a720ebd815983777291bfe3362d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94cac9966ecb86b139a53d99dd405695 |
| publicationDate |
2022-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022401467-A1 |
| titleOfInvention |
Oligonucleotides, compositions and methods thereof |
| abstract |
The present disclosure pertains to the recognition that immune responses mediated by CpG oligonucleotides can be affected by the stereochemistry of modified internucleotidic linkages such as phosphorothioates. In some embodiments, the present disclosure relates to chirally controlled CpG oligonucleotide compositions comprising CpG oligonucleotides comprising multiple modified internucleotidic linkages such as phosphorothioate linkages, wherein the oligonucleotides comprise one or more CpG region motifs having defined stereochemistry patterns of chiral internucleotidic linkages. In some embodiments, CpG oligonucleotides comprising one or more CpG region motifs are capable of agonizing an immune response. In some embodiments, CpG oligonucleotides comprising one or more CpG region motifs are antagonistic. Methods for making and using chirally controlled CpG oligonucleotide compositions are also described. In some embodiments, no immune modulation is desired, and the present disclosure provides methods of identifying chirally controlled oligonucleotide compositions which have decreased immune modulation. |
| priorityDate |
2016-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |